Déjà Vu: CBER Director’s Intervention Saves Sarepta’s Elevidys Again

 
• By Bridget Silverman

Failure of the EMBARK confirmatory trial convinced US FDA reviewers the Duchenne muscular dystrophy gene therapy did not show clinical benefit, but biologics center director Peter Marks invoked totality of evidence to grant full approval.

Boy in wheelchair
FDA expanded use of Elevidys to non-ambulatory DMD patients under accelerated approval. • Source: Shutterstock

More from Approvals

More from Product Reviews